Axsome Therapeutics Inc (AXSM)
74.16
-0.73
(-0.97%)
USD |
NASDAQ |
May 02, 16:00
74.17
+0.01
(+0.01%)
After-Hours: 20:00
Axsome Therapeutics Enterprise Value: 3.305B for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 3.305B |
| May 01, 2024 | 3.340B |
| April 30, 2024 | 3.286B |
| April 29, 2024 | 3.283B |
| April 26, 2024 | 3.189B |
| April 25, 2024 | 3.180B |
| April 24, 2024 | 3.164B |
| April 23, 2024 | 3.254B |
| April 22, 2024 | 3.160B |
| April 19, 2024 | 3.009B |
| April 18, 2024 | 2.905B |
| April 17, 2024 | 3.094B |
| April 16, 2024 | 3.052B |
| April 15, 2024 | 3.023B |
| April 12, 2024 | 3.068B |
| April 11, 2024 | 3.190B |
| April 10, 2024 | 3.154B |
| April 09, 2024 | 3.233B |
| April 08, 2024 | 3.208B |
| April 05, 2024 | 3.215B |
| April 04, 2024 | 3.211B |
| April 03, 2024 | 3.274B |
| April 02, 2024 | 3.324B |
| April 01, 2024 | 3.439B |
| March 28, 2024 | 3.572B |
| Date | Value |
|---|---|
| March 27, 2024 | 3.543B |
| March 26, 2024 | 3.426B |
| March 25, 2024 | 3.456B |
| March 22, 2024 | 3.613B |
| March 21, 2024 | 3.623B |
| March 20, 2024 | 3.527B |
| March 19, 2024 | 3.434B |
| March 18, 2024 | 3.228B |
| March 15, 2024 | 3.371B |
| March 14, 2024 | 3.096B |
| March 13, 2024 | 3.103B |
| March 12, 2024 | 3.079B |
| March 11, 2024 | 3.152B |
| March 08, 2024 | 3.294B |
| March 07, 2024 | 3.205B |
| March 06, 2024 | 3.210B |
| March 05, 2024 | 3.422B |
| March 04, 2024 | 3.497B |
| March 01, 2024 | 3.696B |
| February 29, 2024 | 3.647B |
| February 28, 2024 | 3.722B |
| February 27, 2024 | 3.771B |
| February 26, 2024 | 3.691B |
| February 23, 2024 | 3.532B |
| February 22, 2024 | 3.604B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
552.56M
Minimum
Oct 01 2019
4.415B
Maximum
Feb 12 2024
2.238B
Average
2.503B
Median
Enterprise Value Benchmarks
| Amgen Inc | 202.86B |
| Vertex Pharmaceuticals Inc | 92.15B |
| Krystal Biotech Inc | 4.037B |
| Alnylam Pharmaceuticals Inc | 17.51B |
| Catalyst Pharmaceuticals Inc | 1.633B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -98.65M |
| Revenue (Quarterly) | 71.53M |
| Total Expenses (Quarterly) | 126.60M |
| EPS Diluted (Quarterly) | -2.08 |
| Gross Profit Margin (Quarterly) | 89.69% |
| Profit Margin (Quarterly) | -137.9% |
| Earnings Yield | -7.01% |
| Normalized Earnings Yield | -5.609 |